Skip to main content
Clinical Trials/CTRI/2023/10/058843
CTRI/2023/10/058843
Recruiting
未知

A prospective, interventional, randomized, comparative open-label pivotal clinical study to assess the efficacy of Serioss® as bone void filler/bone substitute.

Serigen Mediproducts Pvt Ltd0 sites0 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Health Condition 1: M844- Pathological fracture, not elsewhere classified
Sponsor
Serigen Mediproducts Pvt Ltd
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional

Investigators

Sponsor
Serigen Mediproducts Pvt Ltd

Eligibility Criteria

Inclusion Criteria

  • To be eligible for the study, patients must fulfill all inclusion criteria listed below:
  • 1 Male and female participants aged above 18 years
  • 2 Patients with any bone void in the extremities (both upper and lower) which requires surgical reconstruction using autografting/ allografting including but not limited to depressed intra articular fracture of upper end of tibia, proximal humerus, distal radius, distal femur, proximal femur and calcaneus; acute traumatic conditions requiring bone void filling surgery / non traumatic conditions like Open wedge osteotomy for deformity correction
  • 3 Full comprehension, willingness to give informed consent and willingness to comply with all the study requirements

Exclusion Criteria

  • Patients meeting any of the following exclusion criteria will not be eligible for participation in
  • 1 Patients with clinically significant medical conditions such as hepatorenal failure, uncontrolled diabetes, long standing steroid intake etc.
  • 2 Patients with active infections of bone or HIV/Hepatitis B/C, pathological fractures.
  • 3 Subject should not have any known history suggestive of hypersensitivity or allergies to the materials used in the product.

Outcomes

Primary Outcomes

Not specified

Similar Trials